Blueprint Medicines Valuation
| BPMC Stock | USD 92.26 0.03 0.03% |
At this time, the firm appears to be overvalued. Blueprint Medicines Corp shows a prevailing Real Value of $76.29 per share. The current price of the firm is $92.26. Our model approximates the value of Blueprint Medicines Corp from analyzing the firm fundamentals such as Profit Margin of (2.03) %, return on equity of -1.57, and Current Valuation of 5.71 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will blend. Key fundamental drivers impacting Blueprint Medicines' valuation include:
Price Book 40.9047 | Enterprise Value 5.7 B | Enterprise Value Ebitda (10.55) | Price Sales 21.4232 | Enterprise Value Revenue 19.9069 |
Overvalued
Today
Please note that Blueprint Medicines' price fluctuation is very steady at this time. Calculation of the real value of Blueprint Medicines Corp is based on 3 months time horizon. Increasing Blueprint Medicines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Blueprint Medicines Corp is useful when determining the fair value of the Blueprint stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Blueprint Medicines. Since Blueprint Medicines is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Blueprint Stock. However, Blueprint Medicines' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 92.26 | Real 76.29 | Target 74.65 | Hype 93.06 | Naive 85.91 |
The real value of Blueprint Stock, also known as its intrinsic value, is the underlying worth of Blueprint Medicines Corp Company, which is reflected in its stock price. It is based on Blueprint Medicines' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Blueprint Medicines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Blueprint Medicines' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Blueprint Medicines Corp helps investors to forecast how Blueprint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Blueprint Medicines more accurately as focusing exclusively on Blueprint Medicines' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Blueprint Medicines' intrinsic value based on its ongoing forecasts of Blueprint Medicines' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Blueprint Medicines' closest peers. When choosing an evaluation method for Blueprint Medicines Corp, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Blueprint Medicines Investments |
|
Blueprint Valuation Trend
Knowing Blueprint Medicines' actual value is paramount for traders to make sound investment determinations. Blueprint Medicines' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Blueprint Medicines' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Blueprint Medicines' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Blueprint Market Cap
Blueprint Medicines Corp is number one stock in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 26.02 Billion. Blueprint Medicines totals roughly 5.61 Billion in market capitalization claiming about 22% of equities under Health Care industry.Blueprint Medicines Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Blueprint Medicines's current stock value. Our valuation model uses many indicators to compare Blueprint Medicines value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Blueprint Medicines competition to find correlations between indicators driving Blueprint Medicines's intrinsic value. More Info.Blueprint Medicines Corp is number one stock in price to earning category among related companies. It is rated third in price to book category among related companies fabricating about 5.16 of Price To Book per Price To Earning. The current year's Price To Book Ratio is expected to grow to 44.91. Comparative valuation analysis is a catch-all model that can be used if you cannot value Blueprint Medicines by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Blueprint Medicines' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Blueprint Medicines' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Blueprint Medicines' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Blueprint Medicines and how it compares across the competition.
About Blueprint Medicines Valuation
The stock valuation mechanism determines the current worth of Blueprint Medicines Corp on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Blueprint Medicines Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Blueprint Medicines Corp based exclusively on its fundamental and basic technical indicators. By analyzing Blueprint Medicines's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Blueprint Medicines's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Blueprint Medicines. We calculate exposure to Blueprint Medicines's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Blueprint Medicines's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 224.9 M | 165.7 M | |
| Pretax Profit Margin | (2.03) | (2.13) | |
| Operating Profit Margin | (1.95) | (2.05) | |
| Net Loss | (2.03) | (2.13) | |
| Gross Profit Margin | 0.90 | 1.02 |
8 Steps to conduct Blueprint Medicines' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Blueprint Medicines' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Blueprint Medicines' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Blueprint Medicines' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Blueprint Medicines' revenue streams: Identify Blueprint Medicines' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Blueprint Medicines' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Blueprint Medicines' growth potential: Evaluate Blueprint Medicines' management, business model, and growth potential.
- Determine Blueprint Medicines' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Blueprint Medicines' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Blueprint Medicines Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Blueprint Medicines does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 60.6 M |
Blueprint Medicines Current Valuation Indicators
Valuation refers to the process of determining the present value of Blueprint Medicines Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Blueprint we look at many different elements of the entity such as Blueprint's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Blueprint Medicines' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Blueprint Medicines' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Blueprint Medicines, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Blueprint Medicines' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Blueprint Medicines' worth.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.